Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which includes patient vignettes regarding the potential treatment implications, highlights the 25% albuminuria reduction demonstrated in FINE-ONE. Faculty underscores the use of albuminuria as a surrogate endpoint, and call for broader access and implementation of therapies shown to offer renal protection so that no patient is left behind when it comes to treatment for CKD.